Drug Type Monoclonal antibody |
Synonyms Anti-TLR2 monoclonal antibody, Anti-Toll-like receptor 2 monoclonal antibody, Tomaralimab + [4] |
Target |
Mechanism TLR2 antagonists(Toll like receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Delayed Graft Function | Phase 2 | DE | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | CZ | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | PL | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | ES | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | GB | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | AT | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | FR | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | US | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | CH | 01 Oct 2012 | |
Delayed Graft Function | Phase 2 | NL | 01 Oct 2012 |
Phase 1/2 | 31 | (nxiejjcqjw) = There is no evidence of treatment related anti-drug antibodies pgzqvilwcy (vrutsrlung ) View more | Positive | 18 May 2017 |